Lupin gets USFDA approval for generic ADHD drug

Pharma Major Lupin said it received final approval from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay.

It had annual sales of approximately USD 66 million in the US.

Clonidine Hydrochloride, the AB rated generic equivalent, is used for the treatment of attention deficit hyperactivity disorder (ADHD) by itself or as adjunctive therapy to stimulant medications.

Lupin develops drugs related to Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and is one of the biggest players in the Anti-TB segment.

It is the 6th largest generics pharmaceutical company by market capitalization by revenues.